Literature summary for 4.6.1.2 extracted from

Soemmer, A.; Sandner, P.; Behrends, S.
BAY 60-2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase Evidence for stable insertion of activator drugs (2018), Biochem. Pharmacol., 147, 10-20 .

Search for more literature for 4.6.1.2

Activating Compound

Activating Compound	Comment	Organism	Structure
BAY 60-2770	activator BAY 60-2770 has higher efficiency on the purified protein than BAY 58-2667, i.e. cinaciguat	Homo sapiens
cinaciguat	i.e. BAY 58-2667. Activator BAY 60-2770 has higher efficiency on the purified protein than BAY 58-2667	Homo sapiens

Cloned(Commentary)

Cloned (Comment)	Organism
transfection of Sf9 cells	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
D530A	mutation in alpha subunit. Protein levels of the catalytically inactive, non-nucleotide binding mutant a1/b1 are not affected by activator drugs	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
GTP	-	Homo sapiens	3',5'-cGMP + diphosphate	-	?

General Information

General Information	Comment	Organism
physiological function	in the presence of activators BAY 58-2667 (cinaciguat) and BAY 60-2770, protein levels of isoforms alpha1/beta1 and alpha2/beta1 overexpressed in Sf9 cells decrease. The activator drugs stably insert into the enzyme during protein biosynthesis independent of the heme redox state	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)